<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11506487</article-id><article-id pub-id-type="pmc">2364094</article-id><article-id pub-id-type="pii">6691972</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.1972</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Liver metastases from colorectal cancer: regional intra-arterial treatment following failure of systemic chemotherapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cyjon</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Neuman-Levin</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rakowsky</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Greif</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Belinky</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Atar</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hardoff</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Brenner</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sulkes</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Institute of Oncology</aff><aff id="aff2"><label>2</label>Departments of Diagnostic Radiology, Unit of Invasive Radiology</aff><aff id="aff3"><label>3</label>Surgery B</aff><aff id="aff4"><label>4</label>Nuclear Medicine and Sackler Faculty of Medicine, Beilinson Campus, Rabin Medical Center, Tel Aviv University, Petah Tiqva 49 100, Tel Aviv, Israel</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: </corresp></author-notes><pub-date pub-type="ppub"><month>08</month><year>2001</year></pub-date><volume>85</volume><issue>4</issue><fpage>504</fpage><lpage>508</lpage><history><date date-type="received"><day>13</day><month>11</month><year>2000</year></date><date date-type="rev-recd"><day>27</day><month>04</month><year>2001</year></date><date date-type="accepted"><day>16</day><month>05</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>This study was designed to determine response rate, survival and toxicity associated with combination chemotherapy delivered intra-arterially to liver in patients with hepatic metastases of colorectal origin refractory to standard systemic treatment. A total of 28 patients who failed prior systemic treatment with fluoropyrimidines received a median of 5 cycles of intra-arterial treatment consisting of 5-fluorouracil 700&#x02008;mg/m<sup>2</sup>/d, leucovorin 120&#x02008;mg/m<sup>2</sup>/d, and cisplatin 20&#x02008;mg/m<sup>2</sup>/d for 5 consecutive days. Cycles were repeated at intervals of 5&#x02013;6 weeks. A major response was achieved in 48&#x00025; of patients: complete response in 8&#x00025; and partial response in 40&#x00025;. The median duration of response was 11.5 months. Median survival was 12 months at a median follow up of 12 months. On multivariate analysis, the only variables with a significant impact on survival were response to treatment and performance status. Toxicity was moderate: grades III&#x02013;IV neutropenia occurred in 29&#x00025; of patients. Most of the patients complained of fatigue lasting for a few days following each cycle. There were no cases of hepatobiliary toxicity. These findings indicate that regional intra-arterial treatment should be considered in selected patients with predominantly liver disease following failure of standard treatment. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>colorectal cancer</kwd><kwd>liver metastases</kwd><kwd>regional intra-arterial</kwd></kwd-group></article-meta></front></article>


